NorthStar is a major producer of the medical radioisotope molybdenum-99 (Mo-99), which is used to generate technetium-99m (Tc-99m). The growth will enable the company to more than double its current Mo-99 processing capabilities, company officials said.
In addition, the developments will advance NorthStar's position as a commercial-scale producer of therapeutic radioisotopes actinium-225 and copper-67, the company said.
Testing of the accelerator production and isotope processing equipment is underway, with commercial production expected at the start of 2023, pending appropriate licensure and U.S Food and Drug Administration approvals.
Copyright © 2021 AuntMinnie.com